Nicholas Berlon, MD
Internal Medicine · Muncie, INNPI 1619361169
Payments from drug & device makers
Across 272 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$996
- Novo Nordisk$374
- Lilly USA, LLC$276
- Pfizer$189
- Bayer$181
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,843100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,097 |
| AbbVie | 67 | $996 |
| Novo Nordisk | 23 | $374 |
| Lilly USA, LLC | 17 | $276 |
| Pfizer | 11 | $189 |
| Bayer | 9 | $181 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $181 |
| Otsuka America Pharmaceutical, Inc. | 8 | $134 |
| Medtronic | 7 | $125 |
| GSK | 8 | $123 |
| Azurity Pharmaceuticals, Inc. | 6 | $118 |
| Boehringer Ingelheim | 6 | $108 |
| Exact Sciences | 6 | $100 |
| Novartis | 6 | $98 |
| Axsome Therapeutics, Inc. | 5 | $87 |
| Astellas Pharma US Inc | 4 | $78 |
| Amneal Pharmaceuticals LLC | 4 | $64 |
| Ardelyx, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 4 | $41 |
| Inari Medical, Inc. | 1 | $39 |
| Abbott | 2 | $31 |
| RGH Enterprises LLC | 1 | $26 |
| Grifols USA, LLC | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| Edwards Lifesciences | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,867 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $90,591 |
| MounjaroTirzepatide | 59 | $73,967 |
| OzempicSemaglutide | 40 | $62,654 |
| FarxigaDapagliflozin Propanediol | 57 | $58,317 |
| JardianceEmpagliflozin | 35 | $51,669 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,782 |
| Potassium Chloride | 21 | $2,617 |
| Atorvastatin Calcium | 264 | $2,457 |
| Duloxetine Hcl | 54 | $2,297 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $2,008 |
| SynthroidLevothyroxine Sodium | 36 | $1,841 |
| Pantoprazole Sodium | 94 | $1,839 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,566 |
| Rosuvastatin Calcium | 93 | $1,481 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $1,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $189 | $91,98177 claims |
| Lilly USA, LLCMounjaro | $276 | $73,96759 claims |
| Novo NordiskOzempic | $374 | $62,65440 claims |
| AstraZenecaFarxiga | $1,097 | $58,31757 claims |
| Boehringer IngelheimJardiance | $108 | $51,66935 claims |
| AbbVieSynthroid | $996 | $1,84136 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $64 | $1,335177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Muncie
- Earl LloydMuncie$23K
- Robert SuerMuncie$20K
- Margaret ZelaskoMuncie$18K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.